Abstract | BACKGROUND: STUDY DESIGN: A prospective institutional database was retrospectively reviewed for short-term complications after IPAA for CUC. Postoperative outcomes were compared between patients who received pre-IPAA IFX and those who did not. RESULTS: Between 2002 and 2005, 47 patients received IFX before IPAA, and 254 patients received none. There were no gender (p = 0.16) or body mass index (p = 0.07) differences between groups. IFX patients were younger than non-IFX patients (mean age 28.1 to 39.3 years) (p < 0.001). In IFX patients, 70% were receiving preoperative IFX, azathioprine, and corticosteroids. Mortality was nil. Overall surgical morbidity was similar: 61.7% and 48.8%, IFX and non-IFX, respectively (p = 0.10). Anastomotic leaks (p = 0.02), pouch-specific (p = 0.01) and infectious (p < 0.01) complications were more common in IFX patients. Multivariable analysis revealed IFX as the only factor independently associated with infectious complications (odds ratio [OR] = 3.5; CI, 1.6-7.5). In a separate analysis, incorporating age, high-dose corticosteroids, azathioprine, and severity of colitis, IFX remained significantly associated with infectious complications (OR = 2.7; CI, 1.1-6.7). CONCLUSIONS: CUC patients treated with IFX before IPAA have substantially increased the odds of postoperative pouch-related and infectious complications. Additional prospective studies are required to determine if IFX alone or other factors contribute to the observed increases in infectious complications.
|
Authors | Chelliah R Selvasekar, Robert R Cima, David W Larson, Eric J Dozois, Jeffrey R Harrington, William S Harmsen, Edward V Loftus Jr, William J Sandborn, Bruce G Wolff, John H Pemberton |
Journal | Journal of the American College of Surgeons
(J Am Coll Surg)
Vol. 204
Issue 5
Pg. 956-62; discussion 962-3
(May 2007)
ISSN: 1072-7515 [Print] United States |
PMID | 17481518
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Gastrointestinal Agents
- Infliximab
|
Topics |
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Chi-Square Distribution
- Chronic Disease
- Colitis, Ulcerative
(surgery)
- Female
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Infliximab
- Logistic Models
- Male
- Postoperative Complications
(drug therapy)
- Proctocolectomy, Restorative
- Retrospective Studies
- Treatment Outcome
|